Summary Safety Review - Loratadine - Abnormal heart rhythm (QT interval prolongation)
Health Canada carried out a safety review to investigate the potential risk of developing an abnormal heart rhythm (QT interval prolongation) with the use of over-the-counter (OTC) drug products containing loratadine. This safety review was triggered by a publication, in the World Health Organization (WHO) Pharmaceuticals NewsletterFootnote1, describing cases of an abnormal heart rhythm (QT interval prolongation) possibly associated with the use of loratadine and desloratadine.
- Publisher
- Health Canada
- Resources
- 3
- Catalogue metadata updated
- 2024-05-09
Data overview
- Formats
- HTML
- File languages
- English, French
Official sources and licences
Resources
- Summary Safety Review - Loratadine - Abnormal heart rhythm (QT interval prolongation) (English, HTML) HTML
- Summary Safety Review - Loratadine - Abnormal heart rhythm (QT interval prolongation) (English, HTML) HTML
- Summary Safety Review - Loratadine - Abnormal heart rhythm (QT interval prolongation) (French, HTML) HTML